$ARIA Stock | News | Financials | Filings | ARIA Forum | November

New Post Public Reply Private Reply Replies (0) Message Board
Langan
$ARIA Ariad Pharmaceuticals Inc. Company Overview

ARIAD Pharmaceuticals, Inc. operates as a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company has four products: Ridaforolimus, Ponatinib, AP1903 and AP26113. Its approach to structure-based drug design has led to three internally discovered, molecularly targeted product candidates for drug-resistant and difficult-to-treat cancers, including certain forms of chronic myeloid leukemia, soft tissue and bone sarcomas and non-small cell lung cancer. ARIAD Pharmaceuticals was founded by Harvey J. Berger in April 1991 and is headquartered in Cambridge, MA.

ARIA Last Price: 4.44

Last Updated: November 28, 2013 8:00 PM EST

ARIA Stock Message Board and Forum http://investorshangout.com/search?q=ARIA&...mp;yt0=Go!

Ariad Pharmaceuticals Inc. ARIA Officers and Executives
Name Age Officer Since Title
Dr. Harvey J. Berger 63 1991 Chairman, President & Chief Executive Officer
Dr. Pierre F. Dodion 58 2007 Senior VP-Corporate Development & Operations
Mr. Edward M. Fitzgerald 58 2002 Chief Financial Officer, Treasurer & Executive VP
Dr. David C. Dalgarno 54 1992 Vice President-Research Technologies
Dr. Timothy P. Clackson 48 1994 Chief Scientific Officer

ARIAD Pharmaceuticals, Inc.
26 Landsdowne Street
Cambridge, Massachusetts 02139-4234
Phone
1 6174940400
Industry
Pharmaceuticals
Sector
Health Care
Fiscal Year-end
12/2013
View SEC Filings Below
Revenue
$558,000
Net Income
$-220.87M
Employees
300.00
Annual Report Below for ARIA

Ariad Pharmaceuticals Inc. ARIA Recent Headlines
MarketWatch News on ARIA
Hewlett-Packard, a cyclical green light and why silver is in trouble 8:50 a.m. Nov. 26, 2013 - Shawn Langlois
Ariad takes another pounding after leukemia treatment is pulled 12:14 p.m. Oct. 31, 2013 - Russ Britt
H-P has best day in four months on upbeat outlook 3:34 p.m. Oct. 9, 2013 - Sue Chang
Ariad plummets 70% after drug test patients have serious clotting issues 10:38 a.m. Oct. 9, 2013 - Russ Britt
FDA places partial hold on Ariad's Iclusig trials 7:16 a.m. Oct. 9, 2013 - MarketWatch.com
Dan Loeb makes bet on Disney 7:06 p.m. Aug. 14, 2013 - David Benoit
Onyx share surge lifts several boats in biotech harbor, including ETFs 10:33 a.m. July 1, 2013 - Russ Britt
SAC Capital Advisors likes this pharma stock 3:24 p.m. April 18, 2013 - Insider Monkey
Ariad Pharma up 6% to $20.09 10:35 a.m. Dec. 17, 2012 - Steve Gelsi
FDA OKs Iclusig to treat rare types of leukemia 1:06 p.m. Dec. 14, 2012 - MarketWatch.com
Stocks: Investors play the waiting game 8:53 a.m. Dec. 11, 2012 - The Trading Deck
12 biotech stocks hit 52-week highs 2:43 p.m. July 27, 2012 - Val Brickates Kennedy
Three rules for short selling 12:01 a.m. Feb. 2, 2012 - The Trading Deck
Stocks to watch Wednesday: C.R. Bard, Papa John’s 6:52 a.m. Dec. 21, 2011 - MarketWatch
Don't be a fan when investing 8:26 a.m. Dec. 20, 2011 - The Trading Deck
Drug stocks move higher in late trading 2:26 p.m. March 24, 2011 - Val Brickates Kennedy
Tuesday’s biggest gaining and declining stocks 5:12 p.m. Jan. 18, 2011 - Kate Gibson
Ariad soars as drug indexes move higher 12:47 p.m. Jan. 18, 2011 - Val Brickates Kennedy
Ariad rallies as drug indexes modestly rise 10:23 a.m. Jan. 18, 2011 - Val Brickates Kennedy
Aria rockets on cancer drug data 9:38 a.m. Jan. 18, 2011 - Val Brickates Kennedy


Four Biotech 'Surprise' Stocks for 2014 7:00 a.m. Nov. 27, 2013 - TheStreet.com
5 Biotechnology Stocks to Buy Now 7:00 a.m. Nov. 27, 2013 - InvestorPlace.com
Wednesday’s Biggest Stock Losers: BLOX, BRLI and More 5:10 a.m. Nov. 27, 2013 - InvestorPlace.com
Ariad Pharmaceuticals (ARIA) In A Perilous Reversal 11:50 a.m. Nov. 26, 2013 - TheStreet.com
Nuance and ARIAD Are Volume Movers for Very Different Reasons 11:24 a.m. Nov. 26, 2013 - 247WallSt.com
Ariad Pharma Appears Cheap Despite Reduced Opportunity 9:19 a.m. Nov. 26, 2013 - Seeking Alpha
Cramer's Lightning Round - What Happened With Ariad Was Jarring (11/25/13) 6:05 a.m. Nov. 26, 2013 - Seeking Alpha
'Mad Money' Lightning Round: Buy, Buy, Buy Splunk 6:00 a.m. Nov. 26, 2013 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: A Glass-Half-Full Market 8:25 p.m. Nov. 25, 2013 - TheStreet.com
Continuation of ARIAD's Iclusig in EU - Analyst Blog 5:00 p.m. Nov. 25, 2013 - Zacks.com
Market Wrap For November 25: Nasdaq Breaks 4,000 Level For First Time Since 2000 3:57 p.m. Nov. 25, 2013 - benzinga.com
ARIAD Shares Skyrocketing With 11 Positive Estimate Revisions 1:35 p.m. Nov. 25, 2013 - Wall St. Cheat Sheet
Why Ariad Pharmaceuticals (ARIA) is Soaring 1:27 p.m. Nov. 25, 2013 - TheStreet.com
Trade-Ideas: Ariad Pharmaceuticals (ARIA) Is Today's "Barbarian At The Gate" Stock 12:36 p.m. Nov. 25, 2013 - TheStreet.com
3 Monday Morning Biotech Movers 12:15 p.m. Nov. 25, 2013 - Wall St. Cheat Sheet
Strength Seen in Ariad Pharmaceuticals (ARIA): Stock Zooms 35.5% - Tale of the Tape 9:39 a.m. Nov. 25, 2013 - Zacks.com
Ariad Pharmaceuticals looks to extend Friday's rally 8:44 a.m. Nov. 25, 2013 - Seeking Alpha
Benzinga's Top #PreMarket Gainers 7:12 a.m. Nov. 25, 2013 - benzinga.com
Ariad Pharmaceuticals Able to Continue Its EU Iclusig Sales 3:05 p.m. Nov. 22, 2013 - benzinga.com
Mid-Afternoon Market Update: Markets on the Rise as Intel Falls 2:34 p.m. Nov. 22, 2013 - benzinga.com


Press Releases on ARIA
Positive Opinion, Program Honorees, Positive Medical Results, and Investor Day - Research Report on Bristol-Myers Squibb, Ariad Pharmaceuticals, Dyax, Ironwood Pharmaceuticals, and Immunomedics 8:00 a.m. Nov. 27, 2013 - PR Newswire
Pre-Market Breakdown: Galena Biopharma Inc., Novavax Inc., Ariad Pharma Inc., and MannKind Corp. 8:00 a.m. Nov. 27, 2013 - PR Newswire
TrendingWallStreet.com Begins Market Coverage on NLY, VEND, ARIA, and FB 12:15 a.m. Nov. 27, 2013 - ACCESSWIRE
Must Watch Stocks: Ariad Pharmaceuticals, Hewlett-Packard Company, Camtek Ltd, Buka Ventures Inc 9:01 a.m. Nov. 26, 2013 - ACCESSWIRE
TrendingWallStreet.com Initiates Analysis on BAC, NVGC, ARIA, and C 12:16 a.m. Nov. 26, 2013 - ACCESSWIRE
ARIA, SIRI, DVAX and UNXL added to NASDAQ Active Stock Watch List at GSR 10:10 a.m. Nov. 25, 2013 - ACCESSWIRE
TrendingWallStreet.com Initiates Coverage on ARIA, TXCC, SFTBY, and TWC 1:38 a.m. Nov. 25, 2013 - ACCESSWIRE
Law Offices of Howard G. Smith Announces a December 9, 2013 Lead Plaintiff Deadline in the Class Action Lawsuit Against ARIAD Pharmaceuticals, Inc. -- ARIA 3:32 p.m. Nov. 22, 2013 - GlobeNewswire
ARIA, MU, AMRN and ARUN added to NASDAQ Active Stock Watch List at EPR 10:19 a.m. Nov. 22, 2013 - ACCESSWIRE
SHAREHOLDER ALERT: Pomerantz Law Firm has filed a Class Action Against ARIAD Pharmaceuticals, Inc. and Certain Officers - ARIA 8:00 a.m. Nov. 22, 2013 - PR Newswire
ARIAD Announces Positive Opinion by the European Medicines Agency on the Continued Availability of Iclusig in Patients with Leukaemias 7:46 a.m. Nov. 22, 2013 - BusinessWire
Financial Results, Agreements, Meetings, and Clinical Trials - Research Report on Cell Therapeutics, Akorn, Ligand, Intercept Pharmaceuticals and Ariad Pharmaceuticals 8:00 a.m. Nov. 20, 2013 - PR Newswire
Must Watch News & Earnings: Tesla Motors Inc, Pan Global Corp, Ariad Pharmaceuticals, Alpha Natural Resources, Brocade Communications Systems 10:23 a.m. Nov. 19, 2013 - PR Newswire
Appointments, Financial Results, Divestitures, and Staff Reductions- Research Report on AstraZeneca, VIVUS, Cooper, ARIAD, and Amarin 8:00 a.m. Nov. 13, 2013 - PR Newswire
Stock Analysis Reports on AMD, ARIA and GSAT 1:20 a.m. Nov. 13, 2013 - ACCESSWIRE
ARIA, DNDN, HSOL and OREX added to NASDAQ Active Stock Watch List at EPR 9:29 a.m. Nov. 12, 2013 - ACCESSWIRE
Shareholder Rights Law Firm Johnson & Weaver, LLP Files Derivative Lawsuit on behalf of ARIAD Pharmaceuticals, Inc. 9:29 a.m. Nov. 12, 2013 - BusinessWire
ARIAD Reports Third Quarter 2013 Financial Results and Announces Significant Expense Reduction 7:35 a.m. Nov. 12, 2013 - BusinessWire
Glancy Binkow & Goldberg Announces a December 9, 2013 Lead Plaintiff Deadline in the Class Action Lawsuit Against ARIAD Pharmaceuticals, Inc. - ARIA 9:10 a.m. Nov. 11, 2013 - GlobeNewswire
News and Updates on ARIA, AFYG and ASAB 1:27 a.m. Nov. 8, 2013 - ACCESSWIRE


Valuation
P/E Current
-3.39
P/E Ratio (with extraordinary items)
-3.23
Price to Sales Ratio
5,670.27
Price to Book Ratio
28.40
Enterprise Value to EBITDA
-2.77
Enterprise Value to Sales
14.66
Total Debt to Enterprise Value
0.00
Efficiency
Revenue/Employee
0.00
Income Per Employee
-0.74
Receivables Turnover
8.27
Total Asset Turnover
0.00
Liquidity
Current Ratio
3.45
Quick Ratio
3.45
Cash Ratio
3.36

Profitability
Operating Margin
-35,888.89
Pretax Margin
-39,582.80
Net Margin
-39,582.80
Return on Assets
-88.19
Return on Equity
-132.66
Return on Total Capital
-123.78
Return on Invested Capital
-125.03
Capital Structure
Total Debt to Total Equity
9.94
Total Debt to Total Capital
9.04
Total Debt to Total Assets
6.22
Long-Term Debt to Equity
8.06
Long-Term Debt to Total Capital
7.33

Ariad Pharmaceuticals Inc. ARIA Financials
Fiscal year is January-December. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 7.08M 8.3M 178.98M 25.3M 558,000
Cost of Goods Sold (COGS) incl. D&A - - - - -
COGS excluding D&A - - - - -
Depreciation & Amortization Expense 3.02M 4.22M 6.15M 4.61M 3.02M
Depreciation 2.27M 3.19M 5.27M 2.91M 2.8M
Amortization of Intangibles 749,000 1.03M 880,000 1.7M 218,000
Gross Income - - - - -

2008 2009 2010 2011 2012 5-year trend
SG&A Expense 75.92M 76.12M 67.93M 97.51M 197.8M
Research & Development 50.84M 63.45M 57.99M 77.74M 139.91M
Other SG&A 25.08M 12.67M 9.95M 19.77M 57.89M
Other Operating Expense 0 0 0 0 0
Unusual Expense 0 7.8M 19.53M 46.72M 20.72M
EBIT after Unusual Expense 0 (7.8M) (19.53M) (46.72M) (20.72M)
Non Operating Income/Expense 0 0 0 0 71,000
Non-Operating Interest Income 1.35M 116,000 86,000 167,000 240,000
Equity in Affiliates (Pretax) 0 0 0 0 -
Interest Expense 550,000 287,000 206,000 232,000 199,000
Gross Interest Expense 550,000 287,000 206,000 232,000 199,000
Interest Capitalized 0 0 0 0 0
Pretax Income (71.05M) (80.01M) 85.25M (123.6M) (220.87M)
Income Tax 0 0 0 0 0
Income Tax - Current Domestic 0 0 0 - -
Income Tax - Current Foreign 0 0 0 0 -
Income Tax - Deferred Domestic 0 0 0 0 -
Income Tax - Deferred Foreign 0 0 0 0 -
Income Tax Credits 0 0 0 0 -
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income (71.05M) (80.01M) 85.25M (123.6M) (220.87M)
Minority Interest Expense 0 0 0 0 0
Net Income (71.05M) (80.01M) 85.25M (123.6M) (220.87M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (71.05M) (80.01M) 85.25M (123.6M) (220.87M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (71.05M) (80.01M) 85.25M (123.6M) (220.87M)
EPS (Basic) (1.02) (0.86) 0.75 (0.93) (1.34)
Basic Shares Outstanding 69.79M 93.33M 113.02M 132.38M 164.96M
EPS (Diluted) (1.02) (0.86) 0.74 (0.93) (1.34)
Diluted Shares Outstanding 69.79M 93.33M 114.73M 132.38M 164.96M
EBITDA (68.84M) (67.81M) 111.05M (72.21M) (197.24M)

Ariad Pharmaceuticals Inc. ARIA Filings
SEC Filings for Ariad Pharmaceuticals Inc.

Filing Date Document Date Type Category Amended
11/22/2013 11/22/2013 8-K Special Events
11/12/2013 09/30/2013 10-Q Quarterly Reports
11/12/2013 N/A SC 13G/A Institutional Ownership *
11/12/2013 11/07/2013 8-K Special Events
11/05/2013 10/31/2013 8-K/A Special Events *
11/01/2013 10/31/2013 8-K Special Events
10/31/2013 10/31/2013 8-K Special Events
10/29/2013 N/A SC 13D N/A
10/23/2013 N/A SC 13G Institutional Ownership
10/18/2013 10/18/2013 8-K Special Events
10/09/2013 10/09/2013 8-K Special Events
09/30/2013 09/28/2013 8-K Special Events
09/18/2013 09/16/2013 8-K Special Events
09/04/2013 09/04/2013 8-K Special Events
08/09/2013 06/30/2013 10-Q Quarterly Reports
08/07/2013 08/07/2013 8-K Special Events
07/17/2013 07/15/2013 8-K Special Events
07/02/2013 07/02/2013 8-K Special Events
06/24/2013 06/20/2013 8-K Special Events
06/04/2013 06/01/2013 8-K Special Events

SEC Filings provided by EDGAR Online, Inc.


ARIA Ariad Pharmaceuticals Inc. Research Links

Stock Message Board http://investorshangout.com/search?q=ARIA&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/ARIA/quote
Stock Chart http://www.otcmarkets.com/stock/ARIA/chart
Company Info http://www.otcmarkets.com/stock/ARIA/company-info
Recent News http://www.otcmarkets.com/stock/ARIA/news
Financials http://www.otcmarkets.com/stock/ARIA/financials
Filings and Disclosure http://www.otcmarkets.com/stock/ARIA/filings
Short Sales http://www.otcmarkets.com/stock/ARIA/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/ARIA/insider-transactions
Research Reports http://www.otcmarkets.com/stock/ARIA/research
Summary http://finance.yahoo.com/q?s=ARIA
Historical Prices http://finance.yahoo.com/q/hp?s=ARIA+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=ARIA
Basic Chart http://finance.yahoo.com/q/bc?s=ARIA+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=ARIA+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=ARIA+Headlines
Press Releases http://finance.yahoo.com/q/p?s=ARIA+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=ARIA+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=ARIA+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=ARIA+Industry
Major Holders http://finance.yahoo.com/q/mh?s=ARIA+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=ARIA+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=ARIA+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=ARIA
Balance Sheet http://finance.yahoo.com/q/bs?s=ARIA
Cash Flow http://finance.yahoo.com/q/cf?s=ARIA+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/ARIA
Market Watch http://www.marketwatch.com/investing/stock/ARIA
Bloomberg http://www.bloomberg.com/quote/ARIA:US
Morningstar http://quotes.morningstar.com/stock/s?t=ARIA
Bussinessweek http://investing.businessweek.com/research/st...icker=ARIA
Barchart http://www.barchart.com/quotes/stocks/ARIA
OTC Short Report http://otcshortreport.com/index.php?index=ARIA
Investopedia http://www.investopedia.com/markets/stocks/ARIA/?wa=0

List of all stock message boards and tickers for NYSE New York Stock Exchange http://investorshangout.com/board?categoryid=NYSE
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nemazee Fellowship Advances Clemency and Justice Reform

Updated Category News Views 74

Nemazee Fellowship: A Catalyst for Change You're probably wondering what's really happening when a couple like Hassan and Nazie Nemazee put their name on a legal fellowship. Skipping the melodrama, it's all about making a dent in the criminal justice system. These two aren't just slapping their name on a plaque—they're throwing real support behind actions that matter....

Continue Reading
Carlos Muñoz Steps Up as HBX Group CEO

Updated Category News Views 96

Changing of the Guard at HBX Group New winds are blowing through HBX Group International PLC as they dump the interim gig and go full throttle with Carlos Muñoz at the helm. From December 1, 2026, this veteran co-founder swaps his non-executive hat for a swankier CEO title, steering the ship into choppy, AI-filled waters. Muñoz's Pedigree: More Than Just a Face in the...

Continue Reading
Golden 1 Credit Union Earns TIME's Top Company Honor

Updated Category News Views 107

A Credit Union Shines in the Limelight Sitting in the honoree section isn't something credit unions are commonly known for, but Sacramento's very own Golden 1 Credit Union just barged into the room with a big win. TIME's inaugural list of America's Best Companies has rolled Golden 1 into the spotlight, solidifying its role not just as a financial leader but as a community...

Continue Reading
Hyperstar's Bold Push: Sales Over Follower Hype

Updated Category News Views 75

A New Era in Influencer Marketing: Hyperstar's Gamble Here's a kicker—follower count is starting to take the back seat, and it's about darn time. Over in Seoul, Hyperstar is shaking up the influencer marketing scene with a new laser focus: not who's got the biggest podium, but who can actually move the product. CEO Euychul Shin seems bent on rewriting the playbook. He...

Continue Reading
Lands' End Brings Holiday Magic to Chicago

Updated Category News Views 351

Something about the first chill in the air can spark that holiday vibe, and Lands' End sure knows how to bottle it. They’ve concocted a hefty dose of festive magic in Chicago with their weekend shindig, a mix of holiday nostalgia, community cheer, and retail bravado. Now, I'm not here to just wax poetic about winter hats and fuzzy pajamas, but this event's got a twinkle...

Continue Reading
Tech Job Market Surges with AI and IT Skills Spike

Updated Category News Views 167

Alright, folks, though we're not drowning in champagne just yet, there's a promising uptick in October's tech employment, signaling a rebound or at least some relief for tech pros and market watchers. CompTIA's numbers show a boost of 7,200 jobs in the tech industry while IT occupations expanded by 26,000 slots. That's no small feat when the general job scene elsewhere...

Continue Reading
Future FinTech Under Investigation: Shareholder Impact Looms

Updated Category News Views 25

Future FinTech Faces Legal Scrutiny When the walls close in under financial suspicion, the spotlight can burn brighter than any anticipated market gain. That's precisely what Future FinTech Group Inc. (NasdaqCM: FTFT) is up against now. Kahn Swick & Foti, LLC, featuring the ex-Attorney General of Louisiana, Charles C. Foti, Jr., has begun scrutinizing the actions of...

Continue Reading
Lilly's Digital Healthcare Push with Hims & Hers

Updated Category News Views 172

Revolutionizing Access: Pharmaceuticals Meet Telehealth In an era where digital disruption is shaking every sector, Eli Lilly (NYSE:LLY) isn't sitting idle. They've just forged a partnership with Hims & Hers (NYSE:HIMS), one that's diving headfirst into the telehealth revolution. We're talking a slick merger of pharmaceuticals and digital platforms—offering FDA-approved...

Continue Reading
Illinois Greenlights Major Water Utility Merger

Updated Category News Views 128

Regulators Signal Green Light for Major Merger When was the last time a deal didn't hit some bumps in the regulatory road? This time, American Water and Essential Utilities are keeping the wheels greased, with the Illinois Commerce Commission giving their merger proposal a thumbs up. It feels like a classic case of utilities sticking to their market playbook—get bigger...

Continue Reading
Tata Power Faces Enforcement Order for $650M Debt

Updated Category News Views 148

Tata's Troubles Escalate Grab a cup of coffee, folks, because this is one rollercoaster of a story that every investor needs to have on their radar. We're talking about Singapore courts coming down on Tata Power like a freight train, with enforcement orders that feel like a page out of a high-stakes drama. The Gavel Drops: What's Happening? The court in Singapore has...

Continue Reading

Top 5 Most Recently Viewed Articles

Emerging Trends and Insights in the CADD Market Growth

Updated Category News Views 156

Understanding the Computer-Aided Drug Design (CADD) Market The computer-aided drug design (CADD) market is on a rapid growth trajectory. This market, flourishing between 2025 and 2034, emphasizes the innovative fusion of technology and healthcare. This growth is driven by increased investments and advancements, leading to improved drug discovery methodologies. Market...

Continue Reading
Transform Your Home with Luxury Custom Cabinets by Calista

Updated Category News Views 310

Elevate Your Kitchen with Custom Cabinets from Calista Homes Calista Homes is renowned for delivering exceptional kitchen remodeling services. Their custom cabinets are designed and crafted in-house, focusing on luxury, quality, and personalized functionality. Each cabinet is a perfect fusion of aesthetics and utility, tailored to fit various styles. The company prides...

Continue Reading
PRophet Launches Groundbreaking Influencer Discovery Tool

Updated Category News Views 192

PRophet Unveils Innovative Influencer Discovery Feature In an era where information spreads rapidly, PRophet is stepping up by integrating a new influencer discovery feature within its acclaimed AI-powered journalist discovery and content creation tool named 'Taylor'. This groundbreaking addition underscores a significant trend where audiences are leaning heavily on...

Continue Reading
Global Remittance Market Expected to Surge by 2032

Updated Category News Views 92

Looking Ahead: The Remittance Market The global remittance market is experiencing significant growth, with projections indicating it could reach an impressive $1,329.92 billion by 2032. This remarkable increase, expected at a compound annual growth rate (CAGR) of 5.8%, highlights a dynamic shift in money transfers across borders. Recent analyses have brought to light...

Continue Reading
Heimar hf. Reports Significant Share Buyback Activity Recently

Updated Category News Views 147

Recent Share Buyback Details from Heimar hf. Heimar hf. has been actively engaging in share buybacks, an essential strategy to enhance shareholder value. Recently, the company acquired 3,000,000 of its own shares at a total expenditure of 108,200,000 ISK. This acquisition is part of a structured buyback program aimed at optimizing its market performance. Breakdown of the...

Continue Reading